Microvision Medical and HeartCon Medtech Selected as Suzhou New District's Outstanding Intellectual Property Cases of 2024

This case belongs to the industrialization of scientific research achievements transformation in universities. The company relies on the "National Key R&D Program" of the Ministry of Science and Technology.Continuously overcoming the challenges in multiple aspects of confocal endoscopy, including fundamental key technology research, product manufacturing and development, core component R&D, and application promotion, a complete industry chain covering "R&D - Production - Application" has been formed, with continuous generation of intellectual property. Adhering to the concept of "continuous innovation for a high-quality life," emphasis is placed on industry-university-research-medical-enterprise collaboration. An integrated technical achievement management system encompassing optics, mechanics, and electronics has been established in the field of confocal endoscopy.

magAssist starts in the field of heart failure and is committed to building a multi-organ failure life support platform.In 2024, faced with a large number of administrative lawsuits for patent invalidation filed by competitors, involving more than 30 patents covering the company's R&D product lines—fully magnetically levitated artificial heart for extracorporeal use and minimally invasive interventional artificial heart—magAssist swiftly formed an "iron triangle" team consisting of patent attorneys, patent engineers, and R&D experts.Through active preparation and scientific validation of the novelty and creativity of its own technology, magAssist secured over 20 favorable verdicts in newly received cases in 2024, with more than 80% involving invention and utility model patent cases. These achievements effectively safeguarded magAssist's intellectual property assets.